Cabaletta Bio Has $299.4 Million To Carry Its Treatment Program Into 2028, Company Says
Research spending rose to $47.1 million as Cabaletta targets a myositis approval application in the first quarter of 2028.
Cabaletta Bio, which develops engineered T cell treatments for autoimmune diseases, reported approximately $299.4 million in cash Thursday and said it expects that money to fund operations into the first quarter of 2028. The company also reported higher research costs and a planned myositis approval application for that quarter in its earnings release accompanying an SEC filing.
Warrant Cash Supports Higher Spending
Third-quarter research and development costs climbed to $47.1 million, compared with $39.8 million a year earlier. Administrative spending also increased, reaching $7.6 million against $6.8 million in the third quarter of 2025.
The September 30 cash balance included approximately $115.0 million received from investors exercising warrants—rights to buy common shares—between July 1 and the warrants’ September 12 expiration. Cabaletta expects its cash to support its operating plan into the same quarter in which it plans to seek FDA approval for myositis.
The company’s quarterly net loss widened to $53.053 million from $44.866 million. For the first nine months, research spending totaled $128.927 million, compared with $106.480 million a year earlier, while administrative costs fell to $22.097 million from $23.150 million.
CABA shares rose about 3% to $1.32 in Friday trading.
Myositis Recruitment Picks Up
Rese-cel, Cabaletta’s lead experimental treatment, uses modified T cells to remove B cells, including those involved in autoimmune disease. The approach aims to reset an immune system that attacks healthy tissue with a single infusion.
Cabaletta expects its 17-patient adult study in dermatomyositis and antisynthetase syndrome, forms of myositis, to produce results in the second half of 2027. The study permits outpatient dosing and is intended to support an FDA approval application in the first quarter of 2028.
“We are now seeing increased enrollment and screening activity,” said Steven Nichtberger, Cabaletta Bio’s chief executive officer. Nichtberger said multiple patients had enrolled in recent weeks; he attributed slower third-quarter recruitment to patient and physician caution that he believes followed safety events reported elsewhere in the field.
Cabaletta plans to include juvenile dermatomyositis results to support a potential pediatric indication and possible eligibility for a Priority Review Voucher. Following a recent FDA interaction, the company said it can also include multi-year adult data on how long responses last; some early-study patients could have three-year follow-up by a potential launch.
Lung Disease Study Opens
Cabaletta has opened an approximately 25-patient systemic sclerosis study focused on associated interstitial lung disease. The study offers outpatient dosing and will primarily assess lung-function improvement without immunomodulators or anti-fibrotic medicines, with either no steroids or a low dose.
Earlier systemic sclerosis results included five patients with interstitial lung disease who, at one year without immunomodulators, had approximately 9% mean improvement in percent-predicted forced vital capacity, a lung-function measure.
In myasthenia gravis, Cabaletta presented results from the first 14 patients treated with rese-cel and preconditioning. Twelve had no cytokine release syndrome, an inflammatory reaction; none had the specified neurological or hemophagocytic inflammatory syndromes. Ten of the 14 achieved a clinically meaningful improvement in daily activities at their latest follow-up while off immunomodulators.
Trials testing rese-cel without preconditioning are enrolling patients with lupus, myasthenia gravis and pemphigus vulgaris. Cabaletta plans to announce its dose and further development strategy in the first half of 2027.
Cabaletta is scheduled to present one-year dermatomyositis results Sunday at American College of Rheumatology Convergence 2026, followed by updated clinical and safety presentations Monday.
Sources
- 8-K Filing — Cabaletta Bio, Inc. (CABA) — SEC EDGAR
- Exhibit caba-ex99_1.htm — Cabaletta Bio, Inc. 8-K exhibit — SEC EDGAR
- Cabaletta Bio Reports Third Quarter 2026 Financial Results — globenewswire.com